Over the past 12 months, 4 insiders at BIOCRYST PHARMACEUTICALS INC filed 11 open-market SEC Form 4 transactions on BCRX: 0 purchases worth $0 and 11 sales worth $4.7M. Insiders have been net sellers over this period. The most recent filing was on May 18, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| May 18, 26 | Amy E McKee | SELL | 11.2K | $8.97 | $100K |
| May 13, 26 | Alane P BarnesChief Legal Officer | SELL | 62.5K | $9.54 | $596K |
| Mar 20, 26 | Theresa HeggieDirector | SELL | 49.9K | $10.11 | $505K |
| Mar 16, 26 | Alane P BarnesChief Legal Officer | SELL | 150.0K | $9.15 | $1.4M |
| Dec 22, 25 | Alane P BarnesChief Legal Officer | SELL | 21.8K | $7.65 | $167K |
| Dec 15, 25 | Alane P BarnesChief Legal Officer | SELL | 21.2K | $7.65 | $162K |
| Dec 3, 25 | Alane P BarnesChief Legal Officer | SELL | 19.8K | $7.65 | $151K |
| Dec 2, 25 | Alane P BarnesChief Legal Officer | SELL | 50.9K | $7.21 | $367K |
| Dec 1, 25 | Alane P BarnesChief Legal Officer | SELL | 91.0K | $7.10 | $646K |
| Nov 13, 25 | Machelle SandersDirector | SELL | 9.6K | $7.14 | $69K |
| Aug 13, 25 | Theresa HeggieDirector | SELL | 70.0K | $8.51 | $596K |
| Dec 13, 24 | Nancy J HutsonDirector | SELL | 7.0K | $7.54 | $53K |
| Jun 24, 24 | Amy E McKeeDirector | SELL | 8.6K | $6.32 | $54K |
| Jun 17, 24 | Machelle SandersDirector | SELL | 4.7K | $6.00 | $28K |
| Jun 14, 24 | Theresa HeggieDirector | SELL | 6.7K | $6.11 | $41K |
| May 30, 24 | Alan G LevinDirector | BUY | 7.9K | $6.36 | $50K |
| May 24, 24 | Steve AselageDirector | BUY | 2.5K | $6.40 | $16K |
| May 20, 24 | Nancy J HutsonDirector | BUY | 5.0K | $6.38 | $32K |
| May 20, 24 | Vincent MilanoDirector | BUY | 15.0K | $6.25 | $94K |
| May 14, 24 | Anthony DoyleChief Financial Officer | BUY | 36.3K | $5.57 | $202K |
| May 14, 24 | Helen M. ThackrayChief R&D Officer | BUY | 30.0K | $5.86 | $176K |
| May 13, 24 | Alane P BarnesChief Legal Officer | BUY | 5.0K | $5.53 | $28K |
| May 13, 24 | Steven K GalsonDirector | BUY | 21.9K | $5.49 | $120K |
| May 13, 24 | Charles K GayerChief Commercial Officer | BUY | 30.0K | $5.47 | $164K |
| May 13, 24 | Jon P StonehousePresident & CEO | BUY | 30.0K | $5.55 | $167K |
| Jun 15, 23 | Machelle SandersDirector | SELL | 4.0K | $7.98 | $32K |
| Jun 14, 23 | Nancy J HutsonDirector | SELL | 12.9K | $8.04 | $103K |
| Apr 3, 23 | Helen M. ThackrayChief R&D Officer | SELL | 7.0K | $8.29 | $58K |
| Feb 1, 23 | Jon P StonehousePresident & CEO | SELL | 100.0K | $10.38 | $1.0M |
| Dec 15, 22 | Alane P BarnesChief Legal Officer | SELL | 4.2K | $10.88 | $45K |
| Dec 15, 22 | Anthony DoyleChief Financial Officer | SELL | 5.7K | $10.90 | $62K |
| Dec 15, 22 | Charles K GayerChief Commercial Officer | SELL | 6.1K | $10.90 | $66K |
| Dec 15, 22 | Michael L JonesExec. Director, Finance - PAO | SELL | 445 | $10.90 | $5K |
| Dec 15, 22 | Jon P StonehousePresident & CEO | SELL | 14.1K | $10.90 | $154K |
| Dec 15, 22 | Helen M. ThackrayChief R&D Officer | SELL | 3.1K | $10.89 | $34K |
| Dec 2, 22 | Jon P StonehousePresident & CEO | SELL | 82.7K | $12.80 | $1.1M |
| Dec 1, 22 | Michael L JonesExec. Director, Finance - PAO | SELL | 8.6K | $13.01 | $112K |
| Dec 1, 22 | Jon P StonehousePresident & CEO | SELL | 214.9K | $13.00 | $2.8M |
| Nov 14, 22 | Yarlagadda S BabuChief Discovery Officer | SELL | 31.5K | $13.88 | $437K |
| Apr 18, 22 | George B AbercrombieDirector | SELL | 5.0K | $11.04 | $55K |
| Apr 1, 22 | Helen M. ThackrayChief R&D Officer | SELL | 7.6K | $16.20 | $123K |
| Mar 10, 22 | William P SheridanChief Medical Officer | SELL | 159.7K | $17.64 | $2.7M |
| Mar 7, 22 | Yarlagadda S BabuChief Discovery Officer | SELL | 20.0K | $17.16 | $343K |
| Mar 1, 22 | Michael L JonesExec. Director, Finance - PAO | SELL | 2.3K | $17.20 | $40K |
| Feb 15, 22 | George B AbercrombieDirector | SELL | 5.0K | $18.50 | $93K |
| Jan 11, 22 | Jon P StonehousePresident & CEO | SELL | 184.0K | $15.04 | $2.8M |
| Dec 7, 21 | Yarlagadda S BabuChief Discovery Officer | SELL | 30.1K | $12.20 | $367K |
| Nov 24, 21 | Vincent MilanoDirector | BUY | 7.5K | $12.19 | $91K |
| Nov 23, 21 | Anthony DoyleChief Financial Officer | BUY | 35.3K | $12.48 | $440K |
| Nov 15, 21 | George B AbercrombieDirector | SELL | 5.0K | $12.27 | $61K |
Over the past 12 months, insiders at BIOCRYST PHARMACEUTICALS INC filed 0 open-market purchases worth $0 and 11 sales worth $4.7M on BCRX, which makes them net sellers over the period. The most recent Form 4 was filed on May 18, 26.
The largest recent open-market BCRX insider purchase in our data was $440K by Anthony Doyle, Chief Financial Officer, filed on Nov 23, 21.
4 different insiders at BIOCRYST PHARMACEUTICALS INC filed open-market SEC Form 4 transactions on BCRX over the last 12 months.
InsiderTape plots every BCRX insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every BIOCRYST PHARMACEUTICALS INC insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →